A Randomised Trial to Evaluate the Efficacy of Low-dose Intracoronary Tenecteplase in ST-Elevation Myocardial Infarction (STEMI) Patients With High Microvascular Resistance Post-percutaneous Coronary Intervention (PCI).
Latest Information Update: 30 Sep 2024
Price :
$35 *
At a glance
- Drugs Tenecteplase (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Acronyms RESTORE-MI
- 26 Oct 2023 Planned number of patients changed from 506 to 445.
- 26 Oct 2023 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
- 26 Oct 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.